# Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC

> **NCT06694129** · — · NOT_YET_RECRUITING · sponsor: **National Cancer Center, China** · enrollment: 40 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- ROS1 Gene Rearrangement
- Resistance
- Targeted Therapy

## Interventions

- **DRUG:** Entrectinib

## Key facts

- **NCT ID:** NCT06694129
- **Lead sponsor:** National Cancer Center, China
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06694129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06694129, "Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06694129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*